Enterococci can incorporate exogenously produced folates and thereby reverse the effect of trimethoprim (TMP) and sulfamethoxazole (SMX); therefore, therapy with these antimicrobials may fail despite apparent in vitro susceptibility (for this reason, TMP / SMX is often left off of susceptibility panels for enterococci).